Julien Soubrier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julien Soubrier has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Abhi Kulkarni
Genetics and Molecular Pathology, SA Pathology Adelaide South Australia Australia
1 shared publication- Adam Benjamin Rohrlach
Max Planck Institute for Evolutionary Anthropology, Department of Archaeogenetics, Leipzig, Germany
1 shared publication - Alan Cooper
Australian Centre for Ancient DNA, The University of Adelaide, Adelaide, South Australia 5005 Australia
1 shared publication - Alice Rogers
Paediatric and Reproductive Genetics Unit Women's and Children's Hospital Adelaide South Australia Australia
1 shared publication - Bastien Llamas
Australian Centre for Ancient DNA, School of Biological Sciences, University of Adelaide, Adelaide, Australia
1 shared publication Calogero M. Santoro
Instituto de Alta Investigación, Universidad de Tarapaca, Arica 1000000, Chile
1 shared publication
Latest Publications
- Open Access
- 5 April 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (5) , 467-474
Extending the new era of genomic testing into pregnancy management: A proposed model for Australian prenatal services
Background: Trio exome sequencing can be used to investigate congenital abnormalities identified on pregnancy ultrasound, but its use in an Australian context has not been assessed.Aims: Assess clinical outcomes and changes in management after expedited genomic testing in the prenatal period to guide the development of a model for widespread implementation.Materials and methods: Forty‐three prospective referrals for whole exome sequencing, including 40 trios (parents and pregnancy), two singletons and one duo were assessed in a tertiary hospital setting with access to a state‐wide pathology laboratory. Diagnostic yield, turn‐around time (TAT), gestational age at reporting, pregnancy outcome, change in management and future pregnancy status were assessed for each family.Results: A clinically significant genomic diagnosis was made in 15/43 pregnancies (35%), with an average TAT of 12 days. Gestational age at time of report ranged from 16 + 5 to 31 + 6 weeks (median 21 + 3 weeks). Molecular diagnoses included neuromuscular and skeletal disorders, RASopathies and a range of other rare Mendelian disorders. The majority of families actively used the results in pregnancy decision making as well as in management of future pregnancies.Conclusions: Rapid second trimester prenatal genomic testing can be successfully delivered to investigate structural abnormalities in pregnancy, providing crucial guidance for current and future pregnancy management. The time‐sensitive nature of this testing requires close laboratory and clinical collaboration to ensure appropriate referral and result communication. We found the establishment of a prenatal coordinator role and dedicated reporting team to be important facilitators. We propose this as a model for genomic testing in other prenatal services.
- 5 April 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (5) , 467-474
Open AccessExtending the new era of genomic testing into pregnancy management: A proposed model for Australian prenatal services
Background: Trio exome sequencing can be used to investigate congenital abnormalities identified on pregnancy ultrasound, but its use in an Australian context has not been assessed.Aims: Assess clinical outcomes and changes in management after expedited genomic testing in the prenatal period to guide the development of a model for widespread implementation.Materials and methods: Forty‐three prospective referrals for whole exome sequencing, including 40 trios (parents and pregnancy), two singletons and one duo were assessed in a tertiary hospital setting with access to a state‐wide pathology laboratory. Diagnostic yield, turn‐around time (TAT), gestational age at reporting, pregnancy outcome, change in management and future pregnancy status were assessed for each family.Results: A clinically significant genomic diagnosis was made in 15/43 pregnancies (35%), with an average TAT of 12 days. Gestational age at time of report ranged from 16 + 5 to 31 + 6 weeks (median 21 + 3 weeks). Molecular diagnoses included neuromuscular and skeletal disorders, RASopathies and a range of other rare Mendelian disorders. The majority of families actively used the results in pregnancy decision making as well as in management of future pregnancies.Conclusions: Rapid second trimester prenatal genomic testing can be successfully delivered to investigate structural abnormalities in pregnancy, providing crucial guidance for current and future pregnancy management. The time‐sensitive nature of this testing requires close laboratory and clinical collaboration to ensure appropriate referral and result communication. We found the establishment of a prenatal coordinator role and dedicated reporting team to be important facilitators. We propose this as a model for genomic testing in other prenatal services.
- Top Cited PapersOpen Access
- 1 April 2016
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 2 (4) , e1501385
Ancient mitochondrial DNA provides high-resolution time scale of the peopling of the Americas
Native American population history is reexamined using a large data set of pre-Columbian mitochondrial genomes.
- 1 April 2016
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 2 (4) , e1501385
Top Cited PapersOpen AccessAncient mitochondrial DNA provides high-resolution time scale of the peopling of the Americas
Native American population history is reexamined using a large data set of pre-Columbian mitochondrial genomes.